Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06457997 · ClinicalTrials.gov registry record · Phase 1
A Study of PHN-010 in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Pheon Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT06457997 is a Phase 1 study that was terminated before completion, run by Pheon Therapeutics. The registered enrollment target is 26 participants.
The verdict
NCT06457997, a Phase 1 study, was terminated before completion, sponsored by Pheon Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-010, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.
Interventions
- DRUG PHN-010
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2024-07-01 |
| Est. Completion | 2025-09-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06457997
The ClinicalTrials.gov registry entry for NCT06457997 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pheon Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PHN-010 is the first listed.
NCT06457997 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06457997 about?
NCT06457997 is a clinical study titled "A Study of PHN-010 in Patients With Advanced Solid Tumors". This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-010, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.
What is the current status of trial NCT06457997?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2024-07-01. Estimated completion is 2025-09-11.
What interventions are being tested in trial NCT06457997?
The interventions under investigation include: PHN-010 (DRUG).
Who is sponsoring clinical trial NCT06457997?
This trial is sponsored by Pheon Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.